Afinitor (everolimus) (DrugBank: Everolimus)
9 diseases告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
34 | 神経線維腫症 | 0 |
67 | 多発性嚢胞腎 | 0 |
89 | リンパ脈管筋腫症 | 0 |
96 | クローン病 | 0 |
137 | 限局性皮質異形成 | 1 |
157 | スタージ・ウェーバー症候群 | 0 |
158 | 結節性硬化症 | 0 |
228 | 閉塞性細気管支炎 | 0 |
277 | リンパ管腫症/ゴーハム病 | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03198949 (ClinicalTrials.gov) | May 24, 2018 | 13/6/2017 | A Study Investigating the Anti-epileptic Efficacy of Afinitor (Everolimus) in Patients With Refractory Seizures Who Have Focal Cortical Dysplasia Type II (FCD II) | A Prospective, Randomized, Double-blind, Placebo-controlled Cross Over Study Investigating the Anti-epileptic Efficacy of Afinitor (Everolimus) in Patients With Refractory Seizures Who Have Focal Cortical Dysplasia Type II (FCD II) | Epilepsy and Focal Cortical Dysplasia II | Drug: Afinitor (everolimus) | Yonsei University | NULL | Recruiting | 4 Years | 40 Years | All | 26 | Phase 2 | Korea, Republic of |